News

Filter

Current filters:

PharmaceuticalMetabolics

1 to 9 of 180 results

Novo Nordisk’s Saxenda gains EU approval for obesity

24-03-2015

There was good news for Danish diabetes care giant Novo Nordisk yesterday, when, late in the day, the…

DiabetesEuropeMetabolicsNovo NordiskPharmaceuticalRegulationSaxendaVictoza

Esperion shares leap on positive Phase IIb results of ETC-1002

Esperion shares leap on positive Phase IIb results of ETC-1002

18-03-2015

Emerging pharma company Esperion Therapeutics has reported positive top-line results from a Phase IIb…

Esperion TherapeuticsETC-1002MetabolicsPharmaceuticalResearch

Novo Nordisk's Saxenda achieves clinically meaningful body weight reduction in Phase IIIa SCALET trial

Novo Nordisk's Saxenda achieves clinically meaningful body weight reduction in Phase IIIa SCALET trial

09-03-2015

New data from Danish insulin giant Novo Nordisk has shown that adults with obesity or who are overweight…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Orexigen shares jump on Contrave trial interim data but FDA orders more cardio studies

Orexigen shares jump on Contrave trial interim data but FDA orders more cardio studies

04-03-2015

The US Food and Drug Administration has said it is “disappointed” by Orexigen Therapeutics’ decision…

ContraveMetabolicsNeurologicalOrexigen TherapeuticsPharmaceuticalRegulationUSA

Arena and Ildong receive marketing authorization for obesity drug Belviq in South Korea

Arena and Ildong receive marketing authorization for obesity drug Belviq in South Korea

03-02-2015

US biopharma company Arena Pharmaceuticals has received marketing authorization in South Korea for Belviq…

Arena PharmaceuticalsBelviqIldong PharmaMetabolicsPharmaceuticalRegulation

Sparse pipeline for acromegaly and gigantism treatment limiting market growth

03-02-2015

The acromegaly and gigantism treatment market will expand at a modest compound annual growth rate (CAGR)…

EuropeMarkets & MarketingMetabolicsNovartisPfizerPharmaceuticalSandostatin LARSigniforSomavertUSA

Rapid expansion forecast for global Cushing’s syndrome drug market

Rapid expansion forecast for global Cushing’s syndrome drug market

29-01-2015

The global Cushing’s syndrome (CS) treatment market will expand rapidly in value from around $179 million…

CortendoEuropeHRA PharmaKetoconazoleMarkets & MarketingMetabolicsNormoCortNovartisPharmaceuticalRare diseasesSigniforUSA

Novo Nordisk gets positive opinion for Saxenda from EMA’s CHMP

Novo Nordisk gets positive opinion for Saxenda from EMA’s CHMP

23-01-2015

Danish diabetes care giant Novo Nordisk revealed yesterday that the European Medicines Agency’s Committee…

DiabetesEuropeMetabolicsNovo NordiskPharmaceuticalRegulationSaxenda

1 to 9 of 180 results

Back to top